(Q45866930)

17 December 2017

title

Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. (English)

1 reference

17 December 2017

0 references

0 references

1 reference

Benny Sørensen

1

1 reference

17 December 2017

Egon Persson

series ordinal

2

1 reference

17 December 2017

Jørgen Ingerslev

series ordinal

3

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

17 December 2017

British Journal of Haematology

published in

1 reference

17 December 2017

volume

137

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

158-165

1 reference

17 December 2017

Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Influence of factor VIIa and phospholipids on coagulation in "acquired" hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

How factor VIIa works in hemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Control of haemostasis with recombinant factor VIIa in patient with inhibitor to factor VIII

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Assignment of molecular properties of a superactive coagulation factor VIIa variant to individual amino acid changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Substitution of valine for leucine 305 in factor VIIa increases the intrinsic enzymatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Augmented intrinsic activity of Factor VIIa by replacement of residues 305, 314, 337 and 374: evidence of two unique mutational mechanisms of activity enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

The P-selectin, tissue factor, coagulation triad

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Thromboelastography and recombinant factor VIIa-hemophilia and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

The epidemiology of inhibitors in haemophilia A: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06534.X

10.1111/J.1365-2141.2007.06534.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017